v3.26.1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2026
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
Name (Title)
Action Taken (Date of Action)
Type of Trading Arrangements
Nature of Trading Arrangements
Duration of Trading Arrangement
Aggregate Number of Securities
Claire Mazumdar, Ph.D. (Chief Executive Officer and Director)
Adoption (March 31, 2026)
Rule 10b5-1 trading arrangement
Sale
Until the earlier of a) December 31, 2026; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.
Up to 150,000 shares of common stock
Ryan Cohlhepp, Pharm.D. (President, Chief Operating Officer and Director)
Adoption (March 31, 2026)
Rule 10b5-1 trading arrangement
Sale
Until the earlier of a) March 1, 2027; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.
Up to 180,000 shares of common stock
Ivan Hyep (Chief Financial Officer and Treasurer )
Adoption (March 31, 2026)
Rule 10b5-1 trading arrangement
Sale
Until the earlier of a) July 8, 2027; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.
Up to 205,000 shares of common stock
Lara Meisner (Chief Legal Officer, Compliance Officer and Corporate Secretary)
Adoption (March 31, 2026)
Rule 10b5-1 trading arrangement
Sale
Until the earlier of a) July 3, 2027; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.
Up to 173,789 shares of common stock
David Raben, M.D. (former Chief Medical Officer)
Adoption (March 31, 2026)
Rule 10b5-1 trading arrangement
Sale
Until the earlier of a) July 1, 2027; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.
Up to 104,000 shares of common stock
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Claire Mazumdan [Member]  
Trading Arrangements, by Individual  
Name Claire Mazumdar
Title Chief Executive Officer and Director
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 31, 2026
Expiration Date December 31, 2026
Arrangement Duration 275 days
Aggregate Available 150,000
Ryan Cohlhepp [Member]  
Trading Arrangements, by Individual  
Name Ryan Cohlhepp
Title President, Chief Operating Officer and Director
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 31, 2026
Expiration Date March 1, 2027
Arrangement Duration 335 days
Aggregate Available 180,000
Ivan Hyep [Member]  
Trading Arrangements, by Individual  
Name Ivan Hyep
Title Chief Financial Officer and Treasurer
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 31, 2026
Expiration Date July 8, 2027
Arrangement Duration 464 days
Aggregate Available 205,000
Lara Meisner [Member]  
Trading Arrangements, by Individual  
Name Lara Meisner
Title Chief Legal Officer, Compliance Officer and Corporate Secretary
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 31, 2026
Expiration Date July 3, 2027
Arrangement Duration 459 days
Aggregate Available 173,789
David Raben [Member]  
Trading Arrangements, by Individual  
Name David Raben
Title Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 31, 2026
Expiration Date July 1, 2027
Arrangement Duration 457 days
Aggregate Available 104,000